Enhancement of type H vessels in bone repair of rat tibial defects treated with stromal vascular fraction-collagen sponge composites.
Mei X., Xu C., Xu Y., Sun H., Luo K., Xiang S.
Animal Study, published in Biomed Mater (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biomed Mater (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42361844
- DOI
- 10.1088/1748-605X/ae834d
Abstract (original English)
To address the clinical limitations of autografts and allografts in bone defect repair, this study aimed to develop a novel composite graft by combining adipose-derived stromal vascular fraction (SVF) with medical-grade collagen sponge, aiming to achieve structural support and functional vascularization simultaneously. A rat tibial defect model was established, and the SVF was combined with medical collagen sponge to form a composite for implantation. In vitro experiments were conducted to detect the proliferation activity, osteogenic differentiation ability, and pro-angiogenic potential of SVF cells. In vivo experiments were used to evaluate the bone volume fraction (BV/TV) and bone mineral density (BMD) in the bone defect area and observe the formation of CD31hi/Emcnhi vessels (H-type vessels). Immunofluorescence staining was performed to analyze the expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). In vitro SVF exhibited robust proliferation, osteogenic differentiation, and secreted factors that significantly enhanced endothelial cell migration and tube formation. In vivo , the SVF-collagen sponge composite significantly increased the bone volume fraction (BV/TV) and BMD at 9 weeks post-operation compared to controls. Importantly, at this 9 week time point, the SVF composite group demonstrated a greater abundance of type H ves
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.